Exploring the Role of Granzyme B in Aging-Related Pruritus: Mechanisms and Therapeutic Potential

Itch, or chronic pruritus, is a common condition affecting about 40% of adults aged 65 and older. For many, chronic pruritus can significantly reduce quality of life. For these individuals, existing treatments like systemic or immunosuppressive drugs are often unsafe due to age-related health conditions. A protein called Granzyme B (GzmB), which is active in aging and inflamed skin, has been linked to itch severity, but its exact role in causing itch is still unknown.
This research aims to uncover how GzmB contributes to itch in aging skin. First, we will study the connection between GzmB levels and signs of itch in skin samples from elderly patients with eczema. Next, we will investigate how GzmB affects skin cells, nerves, and immune responses, focusing on pathways that worsen itch. Finally, we will test a promising new topical GzmB-blocking gel treatment, VTI-1002, in experimental models of itch.
By understanding how GzmB causes itch and testing potential treatments, this study could lead to safe, targeted therapies that improve the quality of life for older adults with chronic itch.